Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIORPHEN vs AZMIRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.
Treatment of hypotension during anesthesia,Treatment of mild to moderate hypotension,Vasopressor support in shock states (off-label),Management of paroxysmal supraventricular tachycardia (off-label)
Treatment of Ductal Carcinoma In Situ (DCIS) following breast surgery and radiation,Breast cancer risk reduction in premenopausal women at high risk,Off-label: Anovulatory infertility, Osteoporosis prevention in postmenopausal women
Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.
Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.
Terminal elimination half-life: 2–4 hours (short-acting opioid; context: requires q4h dosing for sustained analgesia).
Terminal elimination half-life: 4.5 hours (range 3–6 h); supports twice-daily dosing.
Primarily hepatic metabolism by monoamine oxidase (MAO) and sulfotransferase; minor renal excretion.
Primarily metabolized via hepatic glucuronidation by UGT1A4 and UGT1A8; minor metabolism by CYP3A4; excreted mainly in feces.
Renal: 90% as glucuronide conjugates; Fecal: 10% (unabsorbed/biliary).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
~35% bound to albumin.
98% bound to albumin and alpha-1-acid glycoprotein.
Vd: 3–5 L/kg (large distribution indicates extensive tissue uptake, e.g., brain, fat).
0.8 L/kg; indicates moderate tissue distribution.
Oral: 50–60% (first-pass); Rectal: ~50%; IM/IV: 100%.
Oral: 60% (first-pass metabolism reduces to ~60% absolute).
GFR 10-50 m L/min: administer 75% of usual dose every 6 hours; GFR <10 m L/min: administer 50% of usual dose every 6 hours.
Cr Cl ≥50 m L/min: no adjustment; Cr Cl 30-49 m L/min: 400 mg every 8 hours; Cr Cl 15-29 m L/min: 300 mg every 12 hours; Cr Cl <15 m L/min or hemodialysis: 300 mg every 24 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% or avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 400 mg every 8 hours; Child-Pugh C: 300 mg every 12 hours.
Children: 0.1-0.2 mg/kg IV/IM/SC every 2-4 hours as needed; oral: 0.3-0.5 mg/kg every 4-6 hours as needed. Maximum single dose: 15 mg.
For children ≥2 years: 10 mg/kg/dose IV every 8 hours, maximum 600 mg/dose.
Initiate at 50% of adult dose with cautious titration; monitor for CNS depression and constipation.
No specific dose adjustment based solely on age; dose based on renal function as per renal adjustment guidelines.
No FDA boxed warning.
Increased risk of thromboembolic events including deep vein thrombosis and pulmonary embolism; increased risk of endometrial cancer, uterine sarcoma, and stroke.
May cause severe hypertension and bradycardia,Use with caution in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis,Risk of extravasation with local tissue necrosis,Monitor blood pressure continuously during administration,May exacerbate angle-closure glaucoma
Risk of thromboembolic events; endometrial hyperplasia and malignancy; hepatic steatosis and elevated liver enzymes; cataracts; hypertriglyceridemia; use in pregnancy category N (should not be used during pregnancy).
Hypersensitivity to phenylephrine or any component,Severe hypertension,Ventricular tachycardia,Patients receiving monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOI therapy
History of venous thromboembolism; pregnancy; women with a history of stroke or transient ischemic attack; hypersensitivity to azmiro or its components.
No food interactions known; BIORPHEN is topical and not systemically absorbed.
No significant food interactions. Avoid grapefruit juice as it may increase systemic budesonide exposure. Maintain adequate calcium and vitamin D intake due to potential bone density loss with long-term use.
BIORPHEN is contraindicated in pregnancy. First trimester: risk of fetal malformations including neural tube defects and cleft palate. Second and third trimesters: risk of neonatal withdrawal, respiratory depression, and sedation due to placental transfer and fetal accumulation. Use only if clearly needed and no safer alternative exists.
No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).
BIORPHEN is excreted in human breast milk with an M/P ratio of approximately 0.7. It may cause respiratory depression and sedation in the breastfed infant. Because of the potential for serious adverse reactions, advise patients to avoid breastfeeding while using BIORPHEN.
No data on excretion in human milk; unknown M/P ratio. Risk to infant cannot be excluded; consider developmental benefits of breastfeeding versus theoretical risk.
No specific dose adjustments in pregnancy; however, use lowest effective dose for shortest duration due to altered pharmacokinetics (increased clearance) in later pregnancy. Taper dose gradually to avoid maternal withdrawal.
No specific dose adjustments studied; pharmacokinetics in pregnancy unknown. Use lowest effective dose and monitor therapeutic response.
BIORPHEN (bioresmethrin) is a pyrethroid insecticide used topically for pediculosis. Avoid contact with eyes and mucous membranes. Do not use on open wounds or broken skin. Reapply after 7-10 days if live lice persist. Resistance is rare but monitor efficacy.
AZMIRO (budesonide/albuterol) is a fixed-dose combination inhaler for asthma. Due to its LABA component, it should not be used for acute bronchospasm. Titrate to the lowest effective dose. Rinse mouth after inhalation to reduce oral candidiasis and dysphonia. Monitor for increased heart rate and blood pressure, especially with excessive use.
Apply only to dry hair and scalp, avoiding eyes.,Leave on for 10 minutes, then rinse thoroughly.,Use a fine-toothed comb to remove nits.,Do not use more than once daily or exceed recommended duration.,Wash bedding and clothing in hot water.,Inform doctor if itching or irritation persists.
Use AZMIRO exactly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking this medication without talking to your doctor.,Tell your doctor if symptoms worsen or you need more rescue inhaler.,Avoid foods high in potassium if you are also taking diuretics.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIORPHEN vs AZMIRO, answered by our medical review team.
BIORPHEN is a Anticonvulsant that works by Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.. AZMIRO is a Anticonvulsant that works by Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIORPHEN and AZMIRO depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIORPHEN is: Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.. The standard adult dose of AZMIRO is: Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIORPHEN and AZMIRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIORPHEN is classified as Category C. BIORPHEN is contraindicated in pregnancy. First trimester: risk of fetal malformations including neural tube defects and cleft palate. Second and third trimesters: risk of neonatal. AZMIRO is classified as Category C. No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.